论文部分内容阅读
目的 探析转移性结肠癌采用FOLFOXG6化疗方案与贝伐单抗靶向治疗的临床效果.方法 选择2013G3-2014G3期间我院收治的转移性结肠癌患者78例为研究对象,根据随机数字表法将其分为两组,其中给予对照组单一FOLFOXG6化疗方案治疗,而观察组在此基础上,再运用贝伐单抗注射液联合治疗,对两组的治疗效果进行比较分析.结果 与对照组相比,观察组的临床缓解率较高,组间对比有显著差异(P<005);相比较对照组而言,观察组的不良反应发生率较低,但是组间比较无统计学意义(P>005);同时,两组总生存时间和无进展生存时间对比差异显著(P<005).结论 临床上给予转移性结肠癌患者贝伐单抗与FOLFOXG6化疗方案联合治疗,具有不良反应小、疗效确切等优点,可以延长患者的生存时间,值得推广.
Objective To investigate the clinical effects of FOLFOXG6 chemotherapy and targeted therapy with bevacizumab in patients with metastatic colon cancer.Methods 78 patients with metastatic colon cancer who were treated in our hospital from 2013G3-2014G3 were selected as the research object, Divided into two groups, which were given a single FOLFOXG6 chemotherapy treatment group, while the observation group on the basis of this, then the combination of bevacizumab injection treatment, the two groups of treatment were compared.Results Compared with the control group , And the clinical remission rate of the observation group was higher with significant difference between the two groups (P <005). Compared with the control group, the incidence of adverse reactions in the observation group was lower, but there was no significant difference between the two groups (P> 005), meanwhile, there was significant difference between the two groups in the total survival time and the progression-free survival time (P0.005) .Conclusion Bevacizumab combined with FOLFOXG6 chemotherapy in patients with metastatic colon cancer clinically has the advantages of small adverse reaction, curative effect Exactly the advantages of prolonged survival of patients, it is worth promoting.